Lifetime risks of BRCA1/2 mutation carriers have been estimated at approximately 80% for breast cancer and approximately 40% and approximately 20% for ovarian cancer (BRCA1 and BRCA2, respectively) [5]. This evidence concerns the gene BRCA1 and breast cancer.